HIGHLIGHTS
- who: Paul Oster from the Service of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland have published the research work: The Efficacy of Cancer Immunotherapies Is Compromised by Helicobacter pylori Infection, in the Journal: (JOURNAL)
- what: Collectively, pre-clinical and clinical data demonstrate that the gut microbiota plays an important role in enhancing the anti-cancer immune_response following cancer immunotherapies and therefore, is a major research focus for the development of precision medicine and for the improvement of immunotherapy effectiveness.
- future: Studies are necessary to evaluate whether secondary bile . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.